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Summary
The platelet adenosine 5'-diphosphate (ADP) receptor P2Y12 (P2Y12R) plays a critical role in 
platelet aggregation. The present report illustrates an update of dysfunctional platelet P2Y12R 
mutations diagnosed with congenital lifelong bleeding problems. Described patients with 
heterozygous or homozygous substitution in the P2Y12R gene and qualitative abnormalities of the 
platelet P2Y12R are summarized. Recently, a further dysfunctional variant of P2Y12R has been 
identified in two brothers who presented with a lifelong severe bleeding disorder. During in vitro 
aggregation studies, the patient's platelets show a markedly reduced and rapid reversible ADP-
promoted aggregation. A homozygous c.561T>A substitution that changes the codon for His187 to 
Gln (p.His187Gln) in the P2Y12R gene has been identified. This mutation causes no change in 
receptor expression but decreases the affinity of the ligand for the receptor, even at high 
concentrations. Structure modelling studies indicated that the p.His187Gln mutation, located in the 
fifth transmembrane spanning domain (TM5), impairs conformational changes of the receptor. 
Structural integrity of the TM5 region is necessary for agonist and antagonist binding and for 
correct receptor function.
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Zusammenfassung
Der thrombozytäre Adenosin-5'-diphosphat-(ADP)-Rezeptor P2Y12 (P2Y12R) spielt eine 
entscheidende Rolle bei der Thrombozytenaggregation. Im Folgenden soll ein kurzes Update über 
dysfunktionale thrombozytäre P2Y12R-Mutationen, welche im Zusammenhang mit angeborenen, 
lebenslang bestehenden Blutungs-problemen diagnostiziert wurden, gegeben werden. Patienten 
mit bereits beschriebenen homo- und heterozygoten Substitutionen im P2K12-Gen sowie die 
daraus folgenden qualitativen Abnormitäten des thrombozytären P2Y12R werden hier 
zusammengefasst. Zudem wurde kürzlich bei einem Brüderpaar mit einer langjährigen schweren 
Blutungsstörung eine weitere dysfunktionale Variante des P2Y12R identifiziert. In in vitro- 
Aggregationsstudien zeigen die Thrombozyten dieser beiden Patienten eine erheblich reduzierte 
und schnell reversible ADP-induzierte Aggregation. Hierbei wurde eine homozygote c.561T>A 
Substitution, die das Kodon für His187 zu Gln (p.His187Gln) im P2Y12R-Gen verändert, 
nachgewiesen, Die Mutation verursacht dabei keine Änderung der Rezeptorexpression, erhöht aber 
selbst bei einer hohen Ligandenkonzentration die Affinität des Liganden zum Rezeptor. 
„Strukturmodelling”-Studien zeigen, dass die in der fünften Transmembrandomäne (TM5) 
lokalisierte p.His187Gln Mutation die Konformationsänderung des Rezeptors beeinträchtigt, was 
darauf hindeutet, dass die strukturelle Integrität derTM5 Region für die Bindung von Agonisten 
als auch von Antagonisten notwendig ist und damit zu einer normalen Rezeptorfunktion beiträgt.
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P2Y12 is an adenosine 5’-diphosphate (ADP) receptor (P2Y12R) that is mostly expressed at 
platelet surface and mediates the amplification of the platelet activation process necessary to 
achieve full and irreversible aggregation. So far, two human platelet ADP receptors have 
been identified, P2Y1R and P2Y12R, which belong to the seven transmembrane domain 
family of G protein-coupled receptors (1,2).
The P2Y1 receptor-signaling in platelets is mediated by Gq inducing a transient increase in 
intracellular calcium levels by phospholipase Cβ (PLCβ) and activation of the Rho kinases, 
which results in platelet shape change, and the start of reversible platelet activation (Fig. 1) 
(3–5). In contrast, P2Y12R is coupled to Gi. The activation of the P2Y12R by ADP has two 
main consequences: it leads to an inhibition of adenylyl cyclase (AC) and to an activation of 
phosphoinositide 3-kinase (PIK3), which amplifies and sustains the platelet aggregation 
response (2, 6, 7). The coactivation of both the Gq and Gi pathways by ADP is essential for a 
normal platelet aggregation.
The pathways converge to promote activation of the small G protein, Raplb, leading to a 
conformational change of the integrin αIIbβ3 receptor from the inactive to the active form. 
Fibrinogen binds to the activated αIIbβ3, receptor and cross-links platelets (8). Some platelet 
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agonists promote the formation of thromboxane A2 (TxA2) and granule degranulation 
releasing ADP, adenosine 5’-triphosphate (ATP) and serotonin. ADP, serotonin and TxA2 
activate nearby circulating platelets and amplify aggregation (9–11), whereas ATP acts as an 
antagonist (12, 13). P2Y12R plays a critical role in hemostasis and thrombosis (14, 15). This 
function is highlighted by the observation that patients with inherited and pharmacologically 
induced defects of this receptor display a bleeding diathesis of variable severity (1, 16–19). 
Furthermore, patients with clinical manifestations of arterial thrombosis could be protected 
from major adverse cardiovascular events by P2Y12 receptor inhibitors (20).
As consequence P2Y12R is a therapeutic target of effective antiplatelet agents (14).
Inherited P2Y12R defects are autosomal recessive disorders, associated with qualitative or 
quantitative abnormalities of the receptor (1). While no human molecular defect of P2Y1R 
function has been reported, P2Y1 knockout mice have abnormal primary hemostasis (3).
A P2Y12 receptor defect can be hypothesized when ADP, even at high concentrations (≥10 
µmol/I), is unable to induce full and irreversible platelet aggregation, while inducing normal 
shape change. In addition, no fibrinogen binding is detectable after stimulation with ADP 
(0.25–5.0 µmol/l). Tests that evaluate the degree of inhibition of adenylyl cyclase by ADP, 
by measuring either the platelet levels of cyclic AMP or the phosphorylalion of 
vasodilatator-stimulated phosphoprotein (VASP) after the exposure of platelets to 
prostaglandin E1 (PGE1) (VASP phosphorylation analysis), should be used to confirm the 
diagnosis (21).
So far, the following function-modifying mutations in the gene encoding P2Y12R have been 
described (Fig. 1, Tab. 1).
One patient with inherited bleeding problems, displaying two separate heterozygous point 
mutations in two alleles of the gene was identified in 2003 (22). In one allele, a G to A 
transition changes the codon for Arg256 to Gln (p.Arg256Gln) in the sixth transmembrane 
domain (TM6) and, in the other one, a C to T transition changes the codon for Arg265 to Trp 
(p.Arg265Trp) in the third extracellular loop (EL3). Neither the p.Arg256Gln nor the 
p.Arg265Trp variant interfered with receptor surface expression but both blocked receptor 
function. The patient‘s platelets underwent normal ADP-induced shape change, reflecting a 
normal P2Y1R function. The p.Arg256Gln and p.Arg265Trp variants supported normal 
binding to [33P]2MeS-ADP, suggesting a failure in receptor function downstream of agonist 
interaction. The P2Y12R-mediated platelet response to ADP was abnormal with reduced and 
reversible aggregation in response to 4 µmol/l ADP and 20 µmol/l ADP. This study shows 
that the structural integrity of TM6 and EL3 region of the molecule is necessary for normal 
receptor function (22).
Remijn et al. described a further patient with a dysfunctional mutation in EL3 of P2Y12R in 
2007 (23). They identified a heterozygous base pair C to A substitution, changing codon 258 
from praline to threonine (p.Pro258Thr) associated with haemorrhagic diathesis. The patient 
showed no abnormalities regarding platelet count or standard coagulation tests (prothrombin 
time and activated partial thromboplastin time). However, the ADP- and collagen-induced 
platelet aggregation were impaired, confirming that this region of the molecule is important 
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for receptor function. Pro258 has been reported to be involved in conformational change of 
the P2Y12R molecule. Since the p.Pro258Thr substitution alters the protein hydrophobicity, 
size, and rotational mobility, it is likely that this mutation affects the function of P2Y12R to 
this effect (23).
Daly et al. (2009) published another patient who suffers from a mild type 1 von Willebrand 
disease and platelet function defect. He presented with a heterozygous mutation in the 
second extracellular loop of P2Y12R (EL2) which is a region that is important for the 
receptor interaction with ADP (24). This patient showed a tysine to glutamate substitution 
(p.Lys174Glu), which is associated with impairment of platelet, aggregation in response to 
1–10 µmol/l ADP. The reduced and reversible response was associated with markedly 
decreased binding of the ligand [3H]2MeS-ADP to P2Y12R, indicating a role for Lys174 in 
ligand binding and involvement in conformational change of the P2Y12R molecule (24).
In the same laboratory a further missense mutation, predicting a heterozygous p.Pro341Ala 
substitution in the postsynaptic density 957disc large/zonula occludens-l (PDZ)-binding 
motif at the carboxyl terminus of the P2Y12R has been identified in 2009. The PDZ-binding 
domain is necessary for receptor signaling and endocytic sorting. The p.Pro341Ala receptor 
variant exhibits normal ability to inhibit formation of cAMP and normal platelet 
aggregation. However, the authors speculate that this mutation interferes with receptor 
recycling, indicating a role for P341 in intracellular trafficking of the P2Y12R (25).
Patel et al. described a patient with a chronic bleeding disorder expressing a homozygous 
P2Y12R mutation, predicting an arginine to cysteine (p.ArgI22Cys) substitution in 2014 
(26). Argl22 is located in the D(E)RY motif, which is a highly conserved region in G-
protein-coupled receptors that is speculated to be important for regulation of conformational 
changes of the receptor and receptor activation. The patient revealed a normal platelet count 
and normal standard coagulation tests but reduced platelet aggregation in response to ADP 
in result of an impairment of P2Y12R expression and signaling (26).
Recently, we identified a further platelet P2Y12R defect in two brothers with an inherited 
bleeding disorder using functional and molecular genetic analyses (27). We sought to 
determine, whether a novel P2Y12R mutation is the cause for their bleeding abnormalities. 
The index patient is a 45-year old Turkish man with a lifelong hemorrhagic diathesis. He has 
11 siblings who presented with negative, mild or severe bleeding history. His parents are first 
cousins. The patient's bleeding manifestations are recurrent epistaxis, postoperative bleeding 
after tooth extraction and surgical intervention. The patient showed normal values for 
platelet count and standard coagulation tests and for von Willebrand factor antigen and 
ristocetin cofactor activity. Serum thromboxane B2 (TxB2) levels, the platelet contents of 
serotonin, ADP, adenosine 5’ triphosphate (ATP), and fibrinogen were within normal limits. 
TxB2 is a stable metabolite of TxA2 used as a marker of TxA2 generation. His 57 year old 
brother has the same bleeding manifestations and the same homozygous P2Y12R defect 
(27). First, we analysed the aggregation ability and secretion in platelet-rich plasma of the 
index patient, using light transmission and lumi-aggregometry in Milan, Strasbourg and 
Freiburg. The patient's platelets exhibited a markedly reduced and rapidly reversible 
aggregation after stimulation with ADP compared to healthy subjects whose platelets 
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aggregate in an ADP-dose-dependent manner. Typically, platelets of a patient with a P2Y12R 
defect are unable to induce full and irreversible platelet aggregation after stimulation with 
ADP, even at high concentrations (≥10 µmol/l).
The patient‘s platelet shape change was normal in response to ADP, being mediated by 
P2Y1R, with P2Y12R playing no major role (1, 17). After activation by other agonists (i.e. 
collagen, thrombin receptor activating peptide, or thromboxane/prostaglandin endoperoxide) 
the aggregation of the patient's platelets was normal. The binding ability of fibrinogen to 
activated platelets was measured by flow cytometry using fluorescein-conjugated fibrinogen 
after ADP stimulation. The binding of fibrinogen to activated platelets was severely 
impaired compared to healthy subjects (27). Experiments that evaluate the degree of 
inhibition of adenylyl cyclase by ADP were conducted to confirm the diagnosis, by 
measuring the platelet levels of cyclic adenosine S’-monophosphate (cAMP) and the 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP) after exposure of platelets 
to prostaglandin E1 (PGE1) or other stimuli for adenylyl cyclase (1, 21). In the index patient 
no ADP-induced inhibition of cAMP generation occurred (27). Based on the observation 
that ADP failed to inhibit the adenylyl cyclase, it could be concluded that the function of the 
mutated receptor is impaired. Binding experiments performed with the radiolabeled selective 
P2Y12 antagonist [3H]PSB-0413 allow a differentiation between quantitative and qualitative 
abnormalities (28–30). The number of binding sites per platelet was comparable in normal 
and the patient's platelets. Compared to a healthy subject, the brother of the index patient 
showed a reduced affinity of P2Y12R to its ligand measured by competition between 
agonists (ADP or 2-meLhylthioadenosine-5’-diphosphate (2MeSADP)) and the radioligand 
(27). The observation that the patient's platelets had a normal number of binding sites for 
[3H]PSB-0413 despite a severely impaired function of the P2Y12 receptor suggested that a 
deficient receptor was being synthesized. To identify the underlying structural changes of the 
receptor, we analyzed the coding sequence of the P2Y12R gene from genomic DNA by 
amplifying the complete coding sequence of the P2Y12R gene. We identified a homozygous 
c.561T>A substitution that changed the His187 located in the TM5 region of the receptor to 
a Gln (p.His187Gln) (27). Recently, it has been described that the His187 of the P2Y12R 
forms a hydrogen bond with the 2’-OH of 2MeSADP which ultimately leads to the platelet 
activation process (11).
This study outlines the importance of the structural integrity of TM5 region of the P2Y12R 
undergoing conformational changes for a normal receptor function, suggesting that this 
region of the molecule plays a role in signal transduction. His187 is necessary for agonist 
and antagonist binding, as shown by crystallography data and docking results. A 
homozygous mutation of His187 in the P2Y12R results in an inherited severe bleeding 
disorder due to a disrupted P2Y12R-mediated signaling and ultimately impairing platelet 
aggregation (27).
Conclusion
All these described P2Y12R mutations affect amino acids that are essential for receptor 
function. The recently reported crystallographic structures of the human P2Y12R in complex 
with the agonist 2MeS-ADP and the antagonist AZD1283 supported these results (31, 32).
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Fig. 1. 
Simplified receptor signaling in platelet activation: ADP acting via P2Y1 receptor initiates 
platelet shape and aggregation. Activation of the P2Y12 receptor results in amplified and 
sustained aggregation, Hence both P2Y receptors are needed for complete aggregation. ADP, 
adenosine 5'-diphosphate; G, G-protein; PLC, phospholipase CAC, adenylyl cyclase; PI3K, 
phosphoinositide 3-kinase; VASP-P, phosphorylated vasodilator-stimulated phosphoprotein; 
ATP adenosine 5'-triphosphate.
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Fig. 2. 
Secondary structure of the human P2Y12 receptor: Black circles represent P2Y12 receptor 
mutations identified in patients. TM, transmembrane domain; EL, extracellular loop; IL 
intracellular loop.
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